Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
about
Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.New concepts in the treatment and diagnosis of amyloidosis.Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.Light Chain Amyloidosis.Novel Therapies in Light Chain Amyloidosis.Recent advances in understanding and treating immunoglobulin light chain amyloidosis
P2860
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term event-free and overa ...... temic light chain amyloidosis.
@en
Long-term event-free and overa ...... temic light chain amyloidosis.
@nl
type
label
Long-term event-free and overa ...... temic light chain amyloidosis.
@en
Long-term event-free and overa ...... temic light chain amyloidosis.
@nl
prefLabel
Long-term event-free and overa ...... temic light chain amyloidosis.
@en
Long-term event-free and overa ...... temic light chain amyloidosis.
@nl
P2093
P2860
P356
P1433
P1476
Long-term event-free and overa ...... temic light chain amyloidosis.
@en
P2093
R L Comenzo
S M Devlin
P2860
P2888
P304
P356
10.1038/LEU.2016.229
P577
2016-08-18T00:00:00Z